Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. ANSTO - SODIUM IODIDE [131I] THERAPY CAPSULES (50 TO 6000 MBQ) [SIN16117P]

ANSTO - SODIUM IODIDE [131I] THERAPY CAPSULES (50 TO 6000 MBQ) [SIN16117P]

Active ingredients: ANSTO - SODIUM IODIDE [131I] THERAPY CAPSULES (50 TO 6000 MBQ)

Last updated 26 October 2025

Product Info

ANSTO - SODIUM IODIDE [131I] THERAPY CAPSULES (50 TO 6000 MBQ)

[SIN16117P]

Product information

Active Ingredient and Strength

SODIUM IODIDE [I-131] - 50 TO 6,000 MBQ/CAPSULE

Dosage Form

CAPSULE

Manufacturer and Country

ANSTO - AUSTRALIA

Registration Number

SIN16117P

Licence Holder

TRANSMEDIC PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

V10XA01

Indications
Sodium Iodide (131I) Therapy Capsules are indicated in the treatment of hyperthyroidism, and the detection and ablation of residual functioning thyroid tissue in differentiated thyroid carcinoma.

Dose and Administration
The capsules are for oral administration and the dose ranges usually employed are as follows:

Table caption

Thyrotoxicosis

150–600 MBq

Thyroid ablation

800–2000 MBq

Thyroid carcinoma

2000–6000 MBq
(in two capsules)

Contraindications
The use of this therapeutic radiopharmaceutical is absolutely contraindicated in women who are pregnant. Women of reproductive age should have a negative pregnancy test at the time of radionuclide therapy, and should take appropriate contraceptive measures.

The use of therapeutic iodine-131 is not recommended in persons with renal insufficiency, as delayed excretion will result in increased whole body radiation.

This therapy is contraindicated in-patients who are being treated concurrently with thyroid hormone or antithyroid drugs, are vomiting or have diarrhoea.

  • Note: “Iodine allergy” is not a contraindication for use, because of the very small chemical amounts of iodine in therapy capsules (e.g. approx. 3 microgram in a 500 MBq capsule).